Filing Flows

Filing Flows › Companies › Celularity › Cash flow

Celularity cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$1.1M in Q2 2026 · −$8.9M over twelve months

Operating cash flow−$1.1M
Free cash flow−$1.1M
Cash / net income-1.6×
Cash conversion cycle-667 days

Analysis

In Q2 2026, Celularity generated −$1.1M of operating cash flow. That is $109K less than in Q2 2025 (−$999K).

Over the twelve months to Jun 30, 2026, operating cash flow was −$8.9M; the largest uses were operating cash flow ($8.9M); besides operations, cash came from other financing ($8.4M); the cash balance fell by $542K.

Operating cash flow was −$1.1M against net income of $706K — -1.6× profit, less cash than reported earnings, worth checking against working capital. The largest differences: deferred revenue +$6.0M, payables −$4.3M, depreciation & amortization +$1.5M.

Its cash conversion cycle was -667 days (receivables 79 + inventory 23 − payables 769): suppliers fund its working capital.

Free cash flow

Celularity: free cash flow by quarterCelularity: free cash flow by quarter−$144KQ3 2024$1.5MQ4 2024−$3.0MQ1 2025−$999KQ2 2025−$4.2MQ3 2025−$5.1MQ4 2025$1.4MQ1 2026−$1.1MQ2 2026
Operating cash flow less capital spending.
Celularity: operating cash flow against capital spendingCelularity: operating cash flow against capital spendingOperating cash flowCapital spending−$144K$0Q3 2024$1.6M$91KQ4 2024−$3.0M$0Q1 2025−$999K$0Q2 2025−$4.2M$0Q3 2025−$5.1M$0Q4 2025$1.4M$0Q1 2026−$1.1M$0Q2 2026
Latest (Q2 2026): Operating cash flow −$1.1M, Capital spending $0.

Capital allocation, year by year

Celularity: where the cash came from (up) and went (down), by fiscal yearCelularity: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingFY2021: Operating cash flow −$110MFY2021: Shares issued $638KFY2021: Capital spending −$6.2M$638KFY2021FY2022: Operating cash flow −$138MFY2022: Net borrowing $39.2MFY2022: Shares issued $862KFY2022: Capital spending −$5.2M$40.1MFY2022FY2023: Operating cash flow −$38.7MFY2023: Net borrowing −$14.8MFY2023: Shares issued $9.3MFY2023: Capital spending −$1.0M$9.3MFY2023FY2024: Operating cash flow −$6.4MFY2024: Net borrowing −$146KFY2024: Shares issued $58KFY2024: Capital spending −$161K$58KFY2024FY2025: Operating cash flow −$13.3MFY2025: Net borrowing $578KFY2025: Shares issued $1.1M$1.7MFY2025
Over these 5 years operating cash flow totalled −$306M; the largest uses were operating cash flow ($306M) and net borrowing ($15.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$586K
Debt$40.1M
Net debt$39.5M
Due within a year$6.3M
Cash runway1 month

Celularity is burning cash: its operations consume cash, a free cash flow of −$8.9M a year at the current rate against $586K of cash and investments: a runway of about 1 month; $6.3M of debt also comes due within a year, which would need refinancing or new money before any new financing.

Where the cash came from and went

Celularity: sources (+) and uses (−) of cash, Q2 2026Celularity: sources (+) and uses (−) of cash, Q2 2026Operating cash flow−$1.1MOther financing$1.0MCash drawn (+) / kept (−)$83K
Celularity: sources (+) and uses (−) of cash, TTM to Q2 2026Celularity: sources (+) and uses (−) of cash, TTM to Q2 2026Operating cash flow−$8.9MOther financing$8.4MCash drawn (+) / kept (−)$542K

From profit to cash

Celularity: net income to operating cash flow, Q2 2026Celularity: net income to operating cash flow, Q2 2026Net income$706KDepreciation & amortization$1.5MStock-based pay$844KReceivables$1KInventory$659KPayables−$4.3MDeferred revenue$6.0MPrepaid and other assets$216KOperating cash flow−$1.1M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20267923769-667
Q1 2026110321597-1454

Every quarter

QuarterOperating cash flowCapital spendingNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$1.1M———$83K−$1.1M
Q1 2026$1.4M—−$7.0M—$5.9M$1.4M
Q4 2025−$5.1M—−$526K—−$6.1M−$5.1M
Q3 2025−$4.2M—$547K−$1.4M$681K−$4.2M
Q2 2025−$999K———−$632K−$999K
Q1 2025−$3.0M——$2.5M$673K−$3.0M
Q4 2024$1.6M−$91K−$40K—−$646K$1.5M
Q3 2024−$144K———$223K−$144K

Celularity: income statement and cash flow

Celularity, Q2 2026: revenue $5.4M (-5% year over year), operating margin -78.0%. The chart follows the revenue to costs, profit and cash.

Celularity: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.